Lupin receives USFDA’s approval for Tadalafil Tablets

27 Mar 2019 Evaluate

Lupin has received approval for its Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and Company’s Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.

Lupin’s Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg, is the generic equivalent of Eli Lilly and company’s Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg (RLD: Cialis) had annual sales of approximately $1780 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2173.10 4.80 (0.22%)
26-Dec-2024 12:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1826.45
Dr. Reddys Lab 1345.05
Cipla 1478.70
Lupin 2173.10
Zydus Lifesciences 956.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.